B Dharani: What Is the N1 Modifiable Cause of PAD in People With Diabetes?
B Dharani, Diabetologist/ General Physician at Dharani Clinic, shared on LinkedIn:
”What Is the N1 Modifiable Cause of PAD in People With Diabetes?
Smoking.
Peripheral arterial disease (PAD) is a major driver of disability, limb loss, and mortality in people with diabetes.
While several factors contribute, smoking remains the most common and powerful modifiable risk factor.
In individuals with diabetes, smoking:
– Accelerates atherosclerosis
– Causes severe endothelial dysfunction
– Increases inflammation and thrombosis
– Further reduces blood flow to already compromised limbs
The combination of diabetes plus smoking leads to:
– Earlier onset of PAD
– Faster disease progression
– Higher risk of ulcers, critical limb ischemia, and amputations
Yes—glycemic control, blood pressure, and lipids are crucial.
But no single modifiable factor worsens PAD outcomes more consistently than smoking.
Key takeaway:
If we aim to prevent PAD progression and limb loss in diabetes, smoking cessation must be prioritized, not treated as an afterthought.
Sometimes, the most effective intervention isn’t a new drug or device—it’s addressing the risk factor doing the most harm.”

Stay updated with Hemostasis Today.
-
May 28, 2026, 14:14Spelile Mutupira: Why Hemolysis Remains a Major Laboratory Challenge
-
May 28, 2026, 14:08Fredrick Chalinga: The Science Behind Blood Group Immunogenicity
-
May 28, 2026, 14:00Kalyan Roy: The Critical Role of Chelation Therapy in Thalassaemia
-
May 28, 2026, 13:42Claudio Laudani: Balancing Ischemic and Bleeding Risk in AF with Coronary Disease
-
May 28, 2026, 13:30When it Comes to Stroke Care, Quality Matters – Duke Health
-
May 28, 2026, 13:29Natalie Johnson: Transforming PE Care Through Endovascular Innovation
-
May 28, 2026, 13:16Francisco Chacón-Lozsán: Anticoagulation Strategies for Complex ICU Patients
-
May 28, 2026, 12:57Ahmed Kardousha: Protecting Growth and Fertility in Transfusion-Dependent β-Thalassemia
-
May 28, 2026, 12:36Kabilan K L: Key Nursing Considerations for Abciximab Therapy